| P2093 | author name string | Ping Wei | |
| | Xueming Li | |
| | Yonglu Wang | |
| | Liyao Wang | |
| | Yuanlong Xu | |
| | Xiaodan Cheng | |
| P2860 | cites work | Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles | Q28283289 |
| | Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection | Q30831971 |
| | Production and characterization of Hesperetin nanosuspensions for dermal delivery | Q33402012 |
| | Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration | Q33988624 |
| | Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. | Q34184341 |
| | Long-circulating and target-specific nanoparticles: theory to practice | Q34253450 |
| | Paclitaxel and its formulations | Q34552648 |
| | Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs | Q71809729 |
| | Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype | Q72234861 |
| | Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography | Q72311495 |
| | A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique | Q77506295 |
| | Nanosuspensions: a promising drug delivery strategy. | Q35826447 |
| | Nanosuspensions in drug delivery | Q35876031 |
| | Tumoritropic and lymphotropic principles of macromolecular drugs | Q38755702 |
| | Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. | Q40252161 |
| | Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer | Q40397088 |
| | Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity | Q40622688 |
| | Pharmacology and toxicology of Cremophor EL diluent | Q40625207 |
| | Clinical toxicities encountered with paclitaxel (Taxol). | Q40711497 |
| | Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. | Q41586148 |
| | Understanding the structure and stability of paclitaxel nanocrystals | Q41884506 |
| | Hypersensitivity reactions from taxol | Q44119231 |
| | Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. | Q45998080 |
| | Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery | Q46320736 |
| | Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions | Q46776732 |
| | Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. | Q52977773 |
| | Is Cremophor EL, solvent for paclitaxel, cytotoxic? | Q54228749 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | paclitaxel | Q423762 |
| P304 | page(s) | 1497-1507 | |
| P577 | publication date | 2011-07-13 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery | |
| P478 | volume | 6 | |